Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer

Signal Transduction and Targeted Therapy

Volumn 2, Issue , 2017, Pages

  Zhang, Hang ^a,b   Wang, Yuxi ^a   Wu, Yangping ^a   Jiang, Xiaohua ^a   Tao, Yiran ^a   Yao, Yuqin ^a,c,d   Peng, Yujia ^a   Chen, Xiangzheng ^a   Fu, Yuyin ^a   Yu, Lin ^a   Wang, Ruixue ^a   Lai, Qinhuai ^a   Lai, Weirong ^a   Li, Wenting ^a   Kang, Yuhuan ^a   Yi, Shuli ^a   Lu, Ying ^a   Gou, Lantu ^a   Wu, Min ^e   Yang, Jinliang ^a,d  

^a SICHUAN UNIVERSITY   (China)

^b AstsTech (Chengdu) Pharmaceutical Co Ltd   (China)

^c SICHUAN UNIVERSITY   (China)

^d Guangdong Zhongsheng Pharmaceutical Co   (China)

^e UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85023595008     PISSN: 20959907     EISSN: 20593635     Source Type: Journal    
DOI: 10.1038/sigtrans.2017.15     Document Type: Article

References (91)

1. Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y, Verma A. Linked-in: design and efficacy of antibody drug conjugates in oncology. Oncotarget 2013; 4: 397–412.
2. Casi G, Neri D. Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release 2012; 161: 422–428.
3. Flemming A. Antibody engineering: fine-tuning antibody-drug conjugates. Nat Rev Drug Discov 2014; 13: 178–178.
4. Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med 2013; 64: 15–29.
5. Crunkhorn S. Drug design: increasing stability of ADCs. Nat Rev Drug Discov 2014; 13: 812–812.
6. de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B et al. US Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 2012; 18: 5845–5849.
7. Mathew J, Perez EA. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. Curr Opin Oncol 2011; 23: 594–600.
8. Shih C, Padhy L, Murray M, Weinberg RA. Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature 1981; 290: 261–264.
9. Rubin I, Yarden Y. The basic biology of HER2. Ann Oncol 2001; 12(suppl 1): S3–S8.
10. Nuti M, Bellati F, Visconti V, Napoletano C, Domenici L, Caccetta J et al. Immune effects of trastuzumab. J Cancer 2011; 2: 317–323.
11. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127–137.
12. Jørgensen JT, Hersom M. HER2 as a prognostic marker in gastric cancer-a systematic analysis of data from the literature. J Cancer 2012; 3: 137–144.
13. Verri E, Guglielmini P, Puntoni M, Perdelli L, Papadia A, Lorenzi P et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Oncology 2005; 68: 154–161.
14. Grob TJ, Kannengiesser I, Tsourlakis MC, Atanackovic D, Koenig AM, Vashist YK et al. Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung. Mod Pathol 2012; 25: 1566–1573.
15. Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014; 2014: 852748.
16. Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA et al. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res 2012; 18: 546–554.
17. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659–1672.
18. Tan AR, Swain SM. Ongoing adjuvant trials with trastuzumab in breast cancer. Semin Oncol 2003; 30(5 Suppl 16): 54–64.
19. Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687–697.
20. Hubalek M, Brantner C, Marth C. Role of pertuzumab in the treatment of HER2-positive breast cancer. Breast Cancer 2012; 4: 65–73.
21. Moya-Horno I, Cortés J. The expanding role of pertuzumab in the treatment of HER2-positive breast cancer. Breast Cancer 2015; 7: 125.
22. Boyraz B, Sendur MA, Aksoy S, Babacan T, Roach EC, Kizilarslanoglu MC et al. Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Curr Med Res Opin 2013; 29: 405–414.
23. Lambert JM, Chari RV. Ado-trastuzumab emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem 2014; 57: 6949–6964.
24. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733–2743.
25. Cetin B, Benekli M, Turker I, Koral L, Ulas A, Dane F et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer: a multicentre study of Anatolian Society of Medical Oncology (ASMO). J Chemother 2014; 26: 300–305.
26. Robidoux A, Tang G, Rastogi P, Geyer CE, Azar CA, Atkins JN et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14: 1183–1192.
27. Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012; 343: 342–350.
28. Burris HA, Tibbitts J, Holden SN, Sliwkowski MX, Phillips GDL. Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2+ breast cancer. Clin Breast Cancer 2011; 11: 275–282.
29. Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011; 29: 398–405.
30. Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012; 30: 3234–3241.
31. Krop IE, Kim S-B, González-Martín A, LoRusso PM, Ferrero J-M, Smitt M et al. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 689–699.
32. Kupchan SM, Komoda Y, Court W, Thomas G, Smith R, Karim A et al. Tumor inhibitors. LXXIII. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus. J Am Chem Soc 1972; 94: 1354–1356.
33. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367: 1783–1791.
34. Foyil KV, Bartlett NL. Brentuximab vedotin for the treatment of CD30+ lymphomas. Immunotherapy 2011; 3: 475–485.
35. Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30: 2183–2189.
36. Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30: 2190–2196.
37. Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 385: 1853–1862.
38. Azemar M, Schmidt M, Arlt F, Kennel P, Brandt B, Papadimitriou A et al. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Int J Cancer 2000; 86: 269–275.
39. Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN et al. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther 2012; 11: 143–153.
40. Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Res 2009; 69: 8987–8995.
41. Cao Y, Marks JW, Liu Z, Cheung LH, Hittelman WN, Rosenblum MG. Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies. Oncogene 2014; 33: 429–439.
42. Arbabi-Ghahroudi M, Tanha J, MacKenzie R. Prokaryotic expression of antibodies. Cancer Metastasis Rev 2005; 24: 501–519.
43. Furukawa M, Tanaka R, Chuang VTG, Ishima Y, Taguchi K, Watanabe H et al. Human serum albumin-thioredoxin fusion protein with long blood retention property is effective in suppressing lung injury. J Control Release 2011; 154: 189–195.
44. Hoppmann S, Miao Z, Liu S, Liu H, Ren G, Bao A et al. Radiolabeled affibody-albumin bioconjugates for HER2-positive cancer targeting. Bioconjug Chem 2011; 22: 413–421.
45. Yao Y, Su X, Xie Y, Wang Y, Kang T, Gou L et al. Synthesis, characterization, and antitumor evaluation of the albumin-SN38 conjugate. Anti-cancer drugs 2013; 24: 270–277.
46. Kratz F, Warnecke A, Scheuermann K, Stockmar C, Schwab J, Lazar P et al. Probing the cysteine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives. Improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J Med Chem 2002; 45: 5523–5533.
47. Kratz F, Mansour A, Soltau J, Warnecke A, Fichtner I, Unger C et al. Development of albumin-binding doxorubicin prodrugs that are cleaved by prostate-specific antigen. Arch Pharm 2005; 338: 462–472.
48. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008; 132: 171–183.
49. Cai Z, Fu T, Nagai Y, Lam L, Yee M, Zhu Z et al. scFv-based “grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors. Cancer Res 2013; 73: 2619–2627.
50. Longva KE, Pedersen NM, Haslekås C, Stang E, Madshus IH. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer 2005; 116: 359–367.
51. Raja SM, Clubb RJ, Bhattacharyya M, Dimri M, Cheng H, Pan W et al. A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biol Ther 2008; 7: 1630–1640.
52. Hashizume T, Fukuda T, Nagaoka T, Tada H, Yamada H, Watanabe K et al. Cell type dependent endocytic internalization of ErbB2 with an artificial peptide ligand that binds to ErbB2. Cell Biol Int 2008; 32: 814–826.
53. Belimezi MM, Papanastassiou D, Merkouri E, Baxevanis CN, Mamalaki A. Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment. Cancer Immunol Immunother 2006; 55: 1091–1099.
54. Zhu X, Bidlingmaier S, Hashizume R, James CD, Berger MS, Liu B. Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells. Mol Cancer Ther 2010; 9: 2131–2141.
55. Sommaruga S, Lombardi A, Salvadè A, Mazzucchelli S, Corsi F, Galeffi P et al. Highly efficient production of anti-HER2 scFv antibody variant for targeting breast cancer cells. Appl Microbiol Biotechnol 2011; 91: 613–621.
56. Kramer-Marek G, Kiesewetter DO, Capala J. Changes in HER2 expression in breast cancer xenografts after therapy can be quantified using PET and 18 F-labeled affibody molecules. J Nucl Med 2009; 50: 1131–1139.
57. Phillips GDL, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68: 9280–9290.
58. Zhang M, Qiu Z, Li Y, Yang Y, Zhang Q, Xiang Q et al. Construction and characterization of a recombinant human beta defensin 2 fusion protein targeting the epidermal growth factor receptor: in vitro study. Appl Microbiol Biotechnol 2013; 97: 3913–3923.
59. Ducry L, Stump B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem 2009; 21: 5–13.
60. Backliwal G, Hildinger M, Hasija V, Wurm FM. High-density transfection with HEK-293 cells allows doubling of transient titers and removes need for a priori DNA complex formation with PEI. Biotechnol Bioeng 2008; 99: 721–727.
61. Baldi L, Hacker DL, Adam M, Wurm FM. Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives. Biotechnol Lett 2007; 29: 677–684.
62. Cheng L, Sun X, Yi X, Zhang Y. Large-scale plasmid preparation for transient gene expression. Biotechnol Lett 2011; 33: 1559–1564.
63. Fliedl L, Kaisermayer C. Transient gene expression in HEK293 and vero cells immobilised on microcarriers. J Biotechnol 2011; 153: 15–21.
64. Erickson HK, Park PU, Widdison WC, Kovtun YV, Garrett LM, Hoffman K et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006; 66: 4426–4433.
65. Xie H, Audette C, Hoffee M, Lambert JM, Blättler WA. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice. J Pharmacol Exp Ther 2004; 308: 1073–1082.
66. Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004; 10: 7063–7070.
67. Stephan J-P, Chan P, Lee C, Nelson C, Elliott JM, Bechtel C et al. Anti-CD22-MCC-DM1 and MC-MMAF conjugates: impact of assay format on pharmacokinetic parameters determination. Bioconjug Chem 2008; 19: 1673–1683.
68. Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA et al. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer cancer and leukemia group B study 8662. Clin Cancer Res 2001; 7: 2703–2711.
69. Molina MA, Sáez R, Ramsey EE, Garcia-Barchino M-J, Rojo F, Evans AJ et al. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 2002; 8: 347–353.
70. Austin CD, De Mazière AM, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004; 15: 5268–5282.
71. Huang C, Liu Y, Rokita SE. Targeting duplex DNA with the reversible reactivity of quinone methides. Signal Transduct Target Ther 2016; 1: 16009.
72. Smaglo BG, Aldeghaither D, Weiner LM. The development of immunoconjugates for targeted cancer therapy. Nat Rev Clin Oncol 2014; 11: 637–648.
73. Yokota T, Milenic DE, Whitlow M, Wood JF, Hubert SL, Schlom J. Microautoradio-graphic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. Cancer Res 1993; 53: 3776–3783.
74. Pasquetto MV, Vecchia L, Covini D, Digilio R, Scotti C. Targeted drug delivery using immunoconjugates: principles and applications. J Immunother 2011; 34: 611–628.
75. Liu F, Mu J, Xing B. Recent advances on the development of pharmacotherapeutic agents on the basis of human serum albumin. Curr Pharm Des 2015; 21: 1866–1888.
76. Rogers B, Dong D, Li Z, Li Z. Recombinant human serum albumin fusion proteins and novel applications in drug delivery and therapy. Curr Pharm Des 2015; 21: 1899–1907.
77. Qi W-W, Yu H-Y, Guo H, Lou J, Wang Z-M, Liu P et al. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy. Mol Pharm 2015; 12: 675–683.
78. Müller D, Karle A, Meißburger B, Höfig I, Stork R, Kontermann RE. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem 2007; 282: 12650–12660.
79. Hommelgaard AM, Lerdrup M, van Deurs B. Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol Cell 2004; 15: 1557–1567.
80. Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM et al. Influence of affinity and antigen internalization on the uptake and penetration of anti-HER2 antibodies in solid tumors. Cancer Res 2011; 71: 2250–2259.
81. Bertelsen V, Stang E. The mysterious ways of ErbB2/HER2 trafficking. Membranes 2014; 4: 424–446.
82. Citri A, Kochupurakkal BS, Yarden Y. The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 2004; 3: 50–59.
83. Lerdrup M, Hommelgaard AM, Grandal M, van Deurs B. Geldanamycin stimulates internalization of ErbB2 in a proteasome-dependent way. J Cell Sci 2006; 119: 85–95.
84. Pedersen NM, Madshus IH, Haslekås C, Stang E. Geldanamycin-induced down-regulation of ErbB2 from the plasma membrane is clathrin dependent but proteasomal activity independent. Mol Cancer Res 2008; 6: 491–500.
85. Raja SM, Desale SS, Mohapatra B, Luan H, Soni K, Zhang J et al. Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition. Oncotarget 2016; 7: 10522–10535.
86. Perisic O, Webb PA, Holliger P, Winter G, Williams RL. Crystal structure of a diabody, a bivalent antibody fragment. Structure 1994; 2: 1217–1226.
87. Arndt MA, Krauss J, Rybak SM. Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers. FEBS Lett 2004; 578: 257–261.
88. Huston JS, Mudgett-Hunter M, Tai MS, McCartney J, Warren F, Haber E et al. Protein engineering of single-chain Fv analogs and fusion proteins. Methods Enzymol 1991; 203: 46–88.
89. Whitlow M, Bell BA, Feng SL, Filpula D, Hardman KD, Hubert SL et al. An improved linker for single-chain Fv with reduced aggregation andenhanced proteolytic stability. Protein Eng 1993; 6: 989–995.
90. Lu D, Jimenez X, Witte L, Zhu Z. The effect of variable domainorientation and arrangement on the antigen-binding activity of arecombinant human bispecific diabody. Biochem Biophys Res Commun 2004; 318: 507–513.
91. Sheikholvaezin A, Sandstrom P, Eriksson D, Norgren N, Riklund K, Stigbrand T. Optimizing the generation of recombinant single-chainantibodies against placental alkaline phosphatase. Hybridoma 2006; 25: 181–192.